Symbols / KAPA $0.62 +6.69% Kairos Pharma, Ltd.
KAPA Chart
About
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 13.27M |
| Enterprise Value | 7.95M | Income | -5.45M | Sales | — |
| Book/sh | 0.37 | Cash/sh | 0.21 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -1.31 | PEG | — |
| P/S | — | P/B | 1.68 | P/C | — |
| EV/EBITDA | -1.47 | EV/Sales | — | Quick Ratio | 22.57 |
| Current Ratio | 27.07 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.30 | EPS next Y | -0.47 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 16:00 | ROA | -56.59% |
| ROE | -97.99% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 21.41M |
| Shs Float | 12.17M | Short Float | 1.41% | Short Ratio | 0.15 |
| Short Interest | — | 52W High | 2.11 | 52W Low | 0.40 |
| Beta | — | Avg Volume | 535.27K | Volume | 62.49K |
| Target Price | $8.33 | Recom | Strong_buy | Prev Close | $0.58 |
| Price | $0.62 | Change | 6.69% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.33
Mean price target
2. Current target
$0.62
Latest analyst target
3. DCF / Fair value
$-1.78
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.62
Low
$4.00
High
$12.00
Mean
$8.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-19 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-11-04 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-10-20 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-10-07 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-09-19 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-07-16 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-06-04 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-04-17 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-04-03 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2025-03-31 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-03-27 | init | Maxim Group | — → Buy | $4 |
| 2025-03-20 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-02-26 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-02-18 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-02-12 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-01-22 | main | D. Boral Capital | Buy → Buy | $9 |
| 2024-11-14 | main | D. Boral Capital | Buy → Buy | $9 |
| 2024-10-14 | init | EF Hutton | — → Buy | $9 |
- Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy - TipRanks Mon, 02 Mar 2026 08
- symbol__ Stock Quote Price and Forecast - CNN hu, 13 Jun 2024 21
- Kairos Pharma’s Surprising Stock Surge: What’s the Move? - StocksToTrade ue, 15 Jul 2025 07
- Kairos Pharma (KAPA) Short Interest & Short Float | Updated Apr 2026 - MarketBeat hu, 11 Sep 2025 22
- KAPA Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 11
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga ue, 03 Feb 2026 08
- Kairos Pharma to Acquire CL-273 From Celyn; Celyn Gets 16.5% Stake, $15M Milestone, 2% Royalty - TradingView Mon, 02 Mar 2026 08
- Kairos Pharma signs deal for Celyn Therapeutics’ CL-273 - Yahoo Finance ue, 03 Mar 2026 08
- Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal - TipRanks hu, 26 Feb 2026 08
- What is the current Price Target and Forecast for Kairos Pharma, Ltd. (KAPA) - Zacks Investment Research hu, 26 Sep 2024 22
- KAPA Stock Price, Quote & Chart | KAIROS PHARMA LTD (NYSEARCA:KAPA) - ChartMill hu, 14 Nov 2024 10
- Kairos Pharma, Ltd. (KAPA) stock price, news, quote and history - Yahoo Finance UK Wed, 11 Sep 2024 23
- KAPA Stock Price and Chart — AMEX:KAPA - TradingView Sun, 15 Sep 2024 07
- KAPA IPO News - Micro-cap cancer biotech Kairos Pharma prices IPO at $4 - renaissancecapital.com ue, 17 Sep 2024 07
- Kairos Pharma (KAPA) Stock Forecast and Price Target 2026 - MarketBeat hu, 23 Jan 2025 11
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
5.57
+137.81%
|
2.34
+36.70%
|
1.71
+200.18%
|
0.57
|
| Research And Development |
|
2.13
+415.70%
|
0.41
+404.88%
|
0.08
-5.75%
|
0.09
|
| Selling General And Administration |
|
3.28
+85.25%
|
1.77
+20.18%
|
1.47
+354.32%
|
0.32
|
| General And Administrative Expense |
|
3.28
+85.25%
|
1.77
+20.18%
|
1.47
+354.32%
|
0.32
|
| Salaries And Wages |
|
0.34
+55.71%
|
0.22
-76.01%
|
0.91
|
0.00
|
| Other Gand A |
|
2.55
+82.34%
|
1.40
+163.96%
|
0.53
+74.34%
|
0.30
|
| Total Expenses |
|
5.57
+137.81%
|
2.34
+36.70%
|
1.71
+200.18%
|
0.57
|
| Operating Income |
|
-5.57
-137.81%
|
-2.34
-36.70%
|
-1.71
-200.18%
|
-0.57
|
| Total Operating Income As Reported |
|
-5.57
-137.81%
|
-2.34
-36.70%
|
-1.71
-200.18%
|
-0.57
|
| EBITDA |
|
-5.29
-134.56%
|
-2.25
-45.05%
|
-1.55
-260.56%
|
-0.43
|
| Normalized EBITDA |
|
-5.29
-85.31%
|
-2.85
-83.59%
|
-1.55
-260.56%
|
-0.43
|
| Reconciled Depreciation |
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
|
| EBIT |
|
-5.45
-125.64%
|
-2.41
-40.84%
|
-1.71
-190.02%
|
-0.59
|
| Total Unusual Items |
|
0.00
-100.00%
|
0.60
|
0.00
|
—
|
| Total Unusual Items Excluding Goodwill |
|
0.00
-100.00%
|
0.60
|
0.00
|
—
|
| Special Income Charges |
|
0.00
-100.00%
|
0.60
|
0.00
|
—
|
| Other Special Charges |
|
—
|
-0.60
|
—
|
—
|
| Net Income |
|
-5.45
-109.26%
|
-2.60
-43.65%
|
-1.81
-72.57%
|
-1.05
|
| Pretax Income |
|
-5.45
-109.26%
|
-2.60
-43.65%
|
-1.81
-72.57%
|
-1.05
|
| Net Non Operating Interest Income Expense |
|
0.12
+114.55%
|
-0.86
-776.53%
|
-0.10
+79.54%
|
-0.48
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
0.19
+92.86%
|
0.10
-78.65%
|
0.46
|
| Net Interest Income |
|
0.12
+114.55%
|
-0.86
-776.53%
|
-0.10
+79.54%
|
-0.48
|
| Interest Expense |
|
0.00
-100.00%
|
0.19
+92.86%
|
0.10
-78.65%
|
0.46
|
| Interest Income Non Operating |
|
0.12
|
0.00
|
—
|
—
|
| Interest Income |
|
0.12
|
0.00
|
—
|
—
|
| Other Income Expense |
|
—
|
0.60
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-5.45
-109.26%
|
-2.60
-43.65%
|
-1.81
-72.57%
|
-1.05
|
| Net Income From Continuing Operation Net Minority Interest |
|
-5.45
-109.26%
|
-2.60
-43.65%
|
-1.81
-72.57%
|
-1.05
|
| Net Income From Continuing And Discontinued Operation |
|
-5.45
-109.26%
|
-2.60
-43.65%
|
-1.81
-72.57%
|
-1.05
|
| Net Income Continuous Operations |
|
-5.45
-109.26%
|
-2.60
-43.65%
|
-1.81
-72.57%
|
-1.05
|
| Normalized Income |
|
-5.45
-70.11%
|
-3.20
-76.71%
|
-1.81
-72.57%
|
-1.05
|
| Net Income Common Stockholders |
|
-5.45
-109.26%
|
-2.60
-43.65%
|
-1.81
-72.57%
|
-1.05
|
| Diluted EPS |
|
—
|
-0.23
-42.36%
|
-0.16
-61.56%
|
-0.10
|
| Basic EPS |
|
—
|
-0.23
-42.36%
|
-0.16
-61.56%
|
-0.10
|
| Basic Average Shares |
|
—
|
11.36
+1.25%
|
11.22
+3.47%
|
10.84
|
| Diluted Average Shares |
|
—
|
11.36
+1.25%
|
11.22
+3.47%
|
10.84
|
| Diluted NI Availto Com Stockholders |
|
-5.45
-109.26%
|
-2.60
-43.65%
|
-1.81
-72.57%
|
-1.05
|
| Amortization |
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
|
| Amortization Of Intangibles Income Statement |
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
|
| Depreciation Amortization Depletion Income Statement |
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
|
| Depreciation And Amortization In Income Statement |
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
|
| Insurance And Claims |
|
0.39
+154.97%
|
0.15
+420.69%
|
0.03
+45.00%
|
0.02
|
| Total Other Finance Cost |
|
—
|
0.67
+1096.43%
|
0.06
+180.00%
|
0.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
6.54
+13.38%
|
5.77
+497.72%
|
0.96
-6.85%
|
1.04
|
| Current Assets |
|
5.39
+29.22%
|
4.17
+4027.72%
|
0.10
-76.89%
|
0.44
|
| Cash Cash Equivalents And Short Term Investments |
|
4.49
+253.07%
|
1.27
+1267.74%
|
0.09
-78.72%
|
0.44
|
| Cash And Cash Equivalents |
|
4.49
+253.07%
|
1.27
+1267.74%
|
0.09
-78.72%
|
0.44
|
| Cash Financial |
|
—
|
1.27
+1267.74%
|
0.09
-78.72%
|
0.44
|
| Prepaid Assets |
|
0.84
-70.44%
|
2.86
|
0.00
|
0.00
|
| Other Current Assets |
|
0.05
+34.21%
|
0.04
+375.00%
|
0.01
|
—
|
| Total Non Current Assets |
|
1.15
-27.89%
|
1.60
+85.07%
|
0.86
+44.24%
|
0.60
|
| Goodwill And Other Intangible Assets |
|
0.06
-72.07%
|
0.22
-41.88%
|
0.38
-29.52%
|
0.54
|
| Other Intangible Assets |
|
0.06
-72.07%
|
0.22
-41.88%
|
0.38
-29.52%
|
0.54
|
| Non Current Deferred Assets |
|
1.09
-20.77%
|
1.38
+185.68%
|
0.48
+745.61%
|
0.06
|
| Total Liabilities Net Minority Interest |
|
0.20
-79.94%
|
0.99
-67.40%
|
3.04
+37.38%
|
2.21
|
| Current Liabilities |
|
0.20
-79.94%
|
0.99
-58.75%
|
2.40
+47.27%
|
1.63
|
| Payables And Accrued Expenses |
|
0.20
-79.94%
|
0.99
-58.75%
|
2.40
+47.27%
|
1.63
|
| Payables |
|
0.20
-79.94%
|
0.99
-58.75%
|
2.40
+47.27%
|
1.63
|
| Accounts Payable |
|
0.20
-79.94%
|
0.99
-58.68%
|
2.40
+47.39%
|
1.63
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
—
|
| Current Debt |
|
—
|
—
|
—
|
—
|
| Other Current Borrowings |
|
—
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
-100.00%
|
0.64
+9.62%
|
0.58
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.64
+9.62%
|
0.58
|
| Long Term Debt |
|
—
|
—
|
0.64
+9.62%
|
0.58
|
| Stockholders Equity |
|
6.34
+32.77%
|
4.78
+329.84%
|
-2.08
-76.25%
|
-1.18
|
| Common Stock Equity |
|
6.34
+32.77%
|
4.78
+329.84%
|
-2.08
-76.25%
|
-1.18
|
| Capital Stock |
|
0.02
+50.00%
|
0.01
+27.27%
|
0.01
+10.00%
|
0.01
|
| Common Stock |
|
0.02
+50.00%
|
0.01
+27.27%
|
0.01
+10.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
20.82
+51.58%
|
13.74
+6.97%
|
12.84
+0.00%
|
12.84
|
| Ordinary Shares Number |
|
20.82
+51.58%
|
13.74
+6.97%
|
12.84
+0.00%
|
12.84
|
| Additional Paid In Capital |
|
20.58
+51.59%
|
13.58
+229.30%
|
4.12
+28.40%
|
3.21
|
| Retained Earnings |
|
-14.26
-61.79%
|
-8.81
-41.90%
|
-6.21
-41.18%
|
-4.40
|
| Total Equity Gross Minority Interest |
|
6.34
+32.77%
|
4.78
+329.84%
|
-2.08
-76.25%
|
-1.18
|
| Total Capitalization |
|
6.34
+32.77%
|
4.78
+431.67%
|
-1.44
-141.21%
|
-0.60
|
| Working Capital |
|
5.19
+63.30%
|
3.18
+237.89%
|
-2.30
-92.64%
|
-1.20
|
| Invested Capital |
|
6.34
+32.77%
|
4.78
+431.67%
|
-1.44
-141.21%
|
-0.60
|
| Total Debt |
|
—
|
—
|
0.64
+9.62%
|
0.58
|
| Net Debt |
|
—
|
—
|
0.55
+275.86%
|
0.14
|
| Net Tangible Assets |
|
6.28
+37.88%
|
4.55
+285.12%
|
-2.46
-42.94%
|
-1.72
|
| Tangible Book Value |
|
6.28
+37.88%
|
4.55
+285.12%
|
-2.46
-42.94%
|
-1.72
|
| Current Notes Payable |
|
—
|
—
|
—
|
0.00
|
| Dueto Related Parties Current |
|
—
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-3.44
+13.00%
|
-3.96
-4982.72%
|
0.08
+122.95%
|
-0.35
|
| Cash Flow From Continuing Operating Activities |
|
-3.44
+13.00%
|
-3.96
-4982.72%
|
0.08
+122.95%
|
-0.35
|
| Net Income From Continuing Operations |
|
-5.45
-109.26%
|
-2.60
-43.65%
|
-1.81
-72.57%
|
-1.05
|
| Depreciation Amortization Depletion |
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
|
| Amortization Cash Flow |
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
|
| Depreciation And Amortization |
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
|
| Amortization Of Intangibles |
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
+0.00%
|
0.16
|
| Other Non Cash Items |
|
2.65
+498.65%
|
0.44
-54.28%
|
0.97
+137.50%
|
0.41
|
| Stock Based Compensation |
|
—
|
0.22
|
0.00
|
0.00
|
| Operating Gains Losses |
|
—
|
0.03
|
—
|
—
|
| Gain Loss On Investment Securities |
|
—
|
0.03
|
—
|
—
|
| Change In Working Capital |
|
-0.81
+59.38%
|
-1.98
-359.69%
|
0.76
+492.25%
|
0.13
|
| Change In Prepaid Assets |
|
-0.01
+99.46%
|
-2.39
-29750.00%
|
-0.01
|
0.00
|
| Change In Payables And Accrued Expense |
|
-0.79
-296.29%
|
0.40
-47.67%
|
0.77
+498.45%
|
0.13
|
| Change In Other Working Capital |
|
—
|
-2.36
|
—
|
—
|
| Investing Cash Flow |
|
—
|
—
|
—
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
—
|
0.00
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
6.66
+29.72%
|
5.13
+1308.00%
|
-0.42
-159.27%
|
0.72
|
| Cash Flow From Continuing Financing Activities |
|
6.66
+29.72%
|
5.13
+1308.00%
|
-0.42
-159.27%
|
0.72
|
| Net Issuance Payments Of Debt |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.90
|
| Issuance Of Debt |
|
0.00
-100.00%
|
0.14
|
0.00
-100.00%
|
0.93
|
| Repayment Of Debt |
|
—
|
-0.14
|
0.00
+100.00%
|
-0.03
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
0.14
|
0.00
-100.00%
|
0.93
|
| Long Term Debt Payments |
|
—
|
-0.14
|
0.00
+100.00%
|
-0.03
|
| Net Long Term Debt Issuance |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.90
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
5.52
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
3.06
|
0.00
|
—
|
—
|
| Net Other Financing Charges |
|
3.60
+1023.59%
|
-0.39
+8.24%
|
-0.42
-138.76%
|
-0.18
|
| Changes In Cash |
|
3.22
+173.03%
|
1.18
+442.73%
|
-0.34
-194.51%
|
0.36
|
| Beginning Cash Position |
|
1.27
+1267.74%
|
0.09
-78.72%
|
0.44
+498.63%
|
0.07
|
| End Cash Position |
|
4.49
+253.07%
|
1.27
+1267.74%
|
0.09
-78.72%
|
0.44
|
| Free Cash Flow |
|
-3.44
+13.00%
|
-3.96
-4982.72%
|
0.08
+122.95%
|
-0.35
|
| Interest Paid Supplemental Data |
|
0.00
-100.00%
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
0.00
-100.00%
|
5.52
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
5.52
|
0.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-31 View
- 8-K2026-03-02 View
- 8-K2026-02-26 View
- 42025-12-30 View
- 42025-12-23 View
- 42025-11-26 View
- 42025-11-26 View
- 42025-11-26 View
- 42025-11-26 View
- 42025-11-26 View
- 10-Q2025-11-14 View
- 8-K2025-10-15 View
- 8-K2025-10-07 View
- 8-K2025-09-18 View
- 8-K2025-09-11 View
- 8-K2025-09-03 View
- 10-Q2025-08-12 View
- 8-K2025-07-15 View
- 8-K2025-06-12 View
- 8-K2025-06-03 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|